← back to search

Barbara J. Brandhuber

Loxo Oncology at Lilly (United States) · US
Area of research
Molecular Biology · Pathology and Forensic Medicine
Research interest
Research interests include Melanoma and MAPK Pathways, PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy, and Immune Response and Inflammation.
h-index
32
citations
7,174
works
73
NIH funding
primary concept
Chemistry
email

Recent publications

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
Nature Communications 2022cited by 110position: middledoi
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Journal of Thoracic Oncology 2020cited by 280position: middledoi
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
Cancer Discovery 2017cited by 431position: middledoi
Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
Cancer Cell 2014cited by 253position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Steve Sideris · Yale Cancer Center1 papers (2014–2014)Shiva Malek · Yale Cancer Center1 papers (2014–2014) · 1 papers (2014–2014)Jawahar Sudhamsu · Gilead Sciences (United States)1 papers (2014–2014)S.G. Hymowitz · Gene Therapy Laboratory1 papers (2014–2014) · 1 papers (2014–2014)Ariana Peck · California Institute of Technology1 papers (2014–2014)Tony Morales · Loxo Oncology at Lilly (United States)1 papers (2014–2014) · 1 papers (2014–2014) · 1 papers (2014–2014) · 1 papers (2014–2014)Jacob R. Haling · Genomics Institute of the Novartis Research Foundation1 papers (2014–2014)Wendy Sandoval · Genomic Health (United States)1 papers (2014–2014) · 1 papers (2014–2014)